307952-37-0

Upstream product

• 23020-15-7 (1S,2S)-2-phenylcyclopropane-1-carboxylic acid 
• 1013-76-9 1-(2,4-dimethylphenyl)piperazine 
• 131899-86-0 (1S,2S)-2-Phenyl-cyclopropanecarboxylic acid ((S)-1-phenyl-ethyl)-amide 
• 939-87-7 (1SR,2SR)-2-phenylcyclopropanecarbonyl chloride 
• 939-90-2 trans-2-phenylcyclopropane-1-carboxylic acid 
• 763126-74-5 (1R,2S)-1,2-di(hydroxymethyl)-2-phenylcyclopropane 
• 939-89-9 (1R)-1-carboxy-2-phenylcyclopropane 
• 936-98-1 ((R)-2-Phenyl-cyclopropyl)-methanol 
• 63106-93-4 (1S,5R)-1-phenyl-3-oxabicyclo[3.1.0]hexan-2-one 
• 625389-83-5 (1R,2S)-1-[4-(2,4-dimethylphenyl)piperazyl]carbonyl-2-phenylcyclopropane 

Relevant academic research and scientific papers

Construction of a cis-Cyclopropane via Reductive Radical Decarboxylation. Enantioselective Synthesis of cis- and trans-1-Arylpiperazyl-2-phenylcyclopropanes Designed as Antidopaminergic Agents

(1S,2S)-, (1S,2R)-, and (1R,2S)-1-(2,4-Dimethylphenyl)piperazyl-2-phenylcyclopropane (2a, 3, and ent-3, respectively), which were designed as conformationally restricted analogues of haloperidol (1), a clinically effective antipsychotic agent, were synthe

trans-1-[(2-phenylcyclopropyl)methyl]-4-arylpiperazines: Mixed dopamine D2/D4 receptor antagonists as potential antipsychotic agents

The dopaminergic receptor profile of a series of trans-1-[(2-phenylcyclopropyl)methyl]-4-arylpiperazines was examined. Aromatic substitution patterns were varied with the goal of identifying a compound having affinities for the D2 and D4 receptors in a ratio similar to that observed for the atypical neuroleptic clozapine. The compounds (1S,2S)-trans-1-[(2-phenylcyclopropyl)methyl]-4-(2,4-dichlorophenyl)piperazin e (5m) and (1S,2S)-trans-1-[(2-phenylcyclopropyl)methyl]-4-(2,4-dimethylphenyl)piperazin e (5t) were selected for functional antagonists at D2 and D4 receptors and had a D2/D4 ratio approximating that of clozapine; they proved inactive in behavioral tests of antipsychotic activity.